Αποτελέσματα Αναζήτησης
We review the absolute and relative contraindications to IV rtPA for acute ischemic stroke, discussing the underlying rationale and evidence supporting these exclusion criteria. Keywords: acute stroke, thrombolytic therapy, tissue plasminogen activator, contraindications.
Absolute contraindications. Prior intracranial hemorrhage. Known structural cerebral vascular lesion. Known malignant intracranial neoplasm. Ischemic stroke within 3 months (excluding stroke within 3 hours*) Suspected aortic dissection. Active bleeding or bleeding diathesis (excluding menses)
Patients may be treated with intravenous thrombolysis if glucose level is subsequently normalized. § The potential risks of bleeding with tPA from injuries related to the trauma should be weighed against the anticipated benefits of reduced stroke-related neurologic deficits.
19 Φεβ 2021 · advanced imaging. alteplase and tenecteplase. minor and severe strokes. patients over 80 or with previous disability or frailty. potential risk factors for bleeding including use of oral anticoagulants. Watch the below video with the key messages.
30 Οκτ 2019 · The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial.
In this review, we analyze the evidence—most of which is derived from observational research—supporting or contradicting current contraindications for administering IV rtPA to acute ischemic stroke patients. Intravenous recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke is drastically underused.
